Therapeutic strategies targeting cancer stem cells.
Identifieur interne : 001060 ( Main/Corpus ); précédent : 001059; suivant : 001061Therapeutic strategies targeting cancer stem cells.
Auteurs : Xiaoyan Ning ; Jianchang Shu ; Yiqi Du ; Qiwen Ben ; Zhaoshen LiSource :
- Cancer biology & therapy [ 1555-8576 ] ; 2013.
English descriptors
- KwdEn :
- MESH :
- drug effects : Neoplastic Stem Cells.
- drug therapy : Neoplasms.
- pathology : Neoplasms, Neoplastic Stem Cells.
- physiology : Neoplastic Stem Cells.
- therapy : Neoplasms.
- virology : Neoplastic Stem Cells.
- Animals, Humans, Signal Transduction.
Abstract
Increasing studies have demonstrated a small proportion of cancer stem cells (CSCs) exist in the cancer cell population. CSCs have powerful self-renewal capacity and tumor-initiating ability and are resistant to chemotherapy and radiation. Conventional anticancer therapies kill the rapidly proliferating bulk cancer cells but spare the relatively quiescent CSCs, which cause cancer recurrence. So it is necessary to develop therapeutic strategies acting specifically on CSCs. In recent years, studies have shown that therapeutic agents such as metformin, salinomycin, DECA-14, rapamycin, oncostatin M (OSM), some natural compounds, oncolytic viruses, microRNAs, cell signaling pathway inhibitors, TNF-related apoptosis inducing ligand (TRAIL), interferon (IFN), telomerase inhibitors, all-trans retinoic acid (ATRA) and monoclonal antibodies can suppress the self-renewal of CSCs in vitro and in vivo. A combination of these agents and conventional chemotherapy drugs can significantly inhibit tumor growth, metastasis and recurrence. These strategies targeting CSCs may bring new hopes to cancer therapy.
DOI: 10.4161/cbt.23622
PubMed: 23358473
PubMed Central: PMC3667868
Links to Exploration step
pubmed:23358473Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic strategies targeting cancer stem cells.</title><author><name sortKey="Ning, Xiaoyan" sort="Ning, Xiaoyan" uniqKey="Ning X" first="Xiaoyan" last="Ning">Xiaoyan Ning</name><affiliation><nlm:affiliation>Department of Gastroenterology, Changhai Hospital of Second Military Medical University, Shanghai, China.</nlm:affiliation></affiliation></author><author><name sortKey="Shu, Jianchang" sort="Shu, Jianchang" uniqKey="Shu J" first="Jianchang" last="Shu">Jianchang Shu</name></author><author><name sortKey="Du, Yiqi" sort="Du, Yiqi" uniqKey="Du Y" first="Yiqi" last="Du">Yiqi Du</name></author><author><name sortKey="Ben, Qiwen" sort="Ben, Qiwen" uniqKey="Ben Q" first="Qiwen" last="Ben">Qiwen Ben</name></author><author><name sortKey="Li, Zhaoshen" sort="Li, Zhaoshen" uniqKey="Li Z" first="Zhaoshen" last="Li">Zhaoshen Li</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23358473</idno><idno type="pmid">23358473</idno><idno type="doi">10.4161/cbt.23622</idno><idno type="pmc">PMC3667868</idno><idno type="wicri:Area/Main/Corpus">001060</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001060</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic strategies targeting cancer stem cells.</title><author><name sortKey="Ning, Xiaoyan" sort="Ning, Xiaoyan" uniqKey="Ning X" first="Xiaoyan" last="Ning">Xiaoyan Ning</name><affiliation><nlm:affiliation>Department of Gastroenterology, Changhai Hospital of Second Military Medical University, Shanghai, China.</nlm:affiliation></affiliation></author><author><name sortKey="Shu, Jianchang" sort="Shu, Jianchang" uniqKey="Shu J" first="Jianchang" last="Shu">Jianchang Shu</name></author><author><name sortKey="Du, Yiqi" sort="Du, Yiqi" uniqKey="Du Y" first="Yiqi" last="Du">Yiqi Du</name></author><author><name sortKey="Ben, Qiwen" sort="Ben, Qiwen" uniqKey="Ben Q" first="Qiwen" last="Ben">Qiwen Ben</name></author><author><name sortKey="Li, Zhaoshen" sort="Li, Zhaoshen" uniqKey="Li Z" first="Zhaoshen" last="Li">Zhaoshen Li</name></author></analytic><series><title level="j">Cancer biology & therapy</title><idno type="eISSN">1555-8576</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Humans (MeSH)</term><term>Neoplasms (drug therapy)</term><term>Neoplasms (pathology)</term><term>Neoplasms (therapy)</term><term>Neoplastic Stem Cells (drug effects)</term><term>Neoplastic Stem Cells (pathology)</term><term>Neoplastic Stem Cells (physiology)</term><term>Neoplastic Stem Cells (virology)</term><term>Signal Transduction (MeSH)</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neoplastic Stem Cells</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neoplasms</term><term>Neoplastic Stem Cells</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Neoplastic Stem Cells</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Neoplastic Stem Cells</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Signal Transduction</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Increasing studies have demonstrated a small proportion of cancer stem cells (CSCs) exist in the cancer cell population. CSCs have powerful self-renewal capacity and tumor-initiating ability and are resistant to chemotherapy and radiation. Conventional anticancer therapies kill the rapidly proliferating bulk cancer cells but spare the relatively quiescent CSCs, which cause cancer recurrence. So it is necessary to develop therapeutic strategies acting specifically on CSCs. In recent years, studies have shown that therapeutic agents such as metformin, salinomycin, DECA-14, rapamycin, oncostatin M (OSM), some natural compounds, oncolytic viruses, microRNAs, cell signaling pathway inhibitors, TNF-related apoptosis inducing ligand (TRAIL), interferon (IFN), telomerase inhibitors, all-trans retinoic acid (ATRA) and monoclonal antibodies can suppress the self-renewal of CSCs in vitro and in vivo. A combination of these agents and conventional chemotherapy drugs can significantly inhibit tumor growth, metastasis and recurrence. These strategies targeting CSCs may bring new hopes to cancer therapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23358473</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-8576</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Cancer biology & therapy</Title><ISOAbbreviation>Cancer Biol Ther</ISOAbbreviation></Journal><ArticleTitle>Therapeutic strategies targeting cancer stem cells.</ArticleTitle><Pagination><MedlinePgn>295-303</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4161/cbt.23622</ELocationID><Abstract><AbstractText>Increasing studies have demonstrated a small proportion of cancer stem cells (CSCs) exist in the cancer cell population. CSCs have powerful self-renewal capacity and tumor-initiating ability and are resistant to chemotherapy and radiation. Conventional anticancer therapies kill the rapidly proliferating bulk cancer cells but spare the relatively quiescent CSCs, which cause cancer recurrence. So it is necessary to develop therapeutic strategies acting specifically on CSCs. In recent years, studies have shown that therapeutic agents such as metformin, salinomycin, DECA-14, rapamycin, oncostatin M (OSM), some natural compounds, oncolytic viruses, microRNAs, cell signaling pathway inhibitors, TNF-related apoptosis inducing ligand (TRAIL), interferon (IFN), telomerase inhibitors, all-trans retinoic acid (ATRA) and monoclonal antibodies can suppress the self-renewal of CSCs in vitro and in vivo. A combination of these agents and conventional chemotherapy drugs can significantly inhibit tumor growth, metastasis and recurrence. These strategies targeting CSCs may bring new hopes to cancer therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ning</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Changhai Hospital of Second Military Medical University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shu</LastName><ForeName>Jianchang</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Yiqi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Ben</LastName><ForeName>Qiwen</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhaoshen</ForeName><Initials>Z</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Biol Ther</MedlineTA><NlmUniqueID>101137842</NlmUniqueID><ISSNLinking>1538-4047</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cancer stem cell</Keyword><Keyword MajorTopicYN="N">target</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23358473</ArticleId><ArticleId IdType="pii">23622</ArticleId><ArticleId IdType="doi">10.4161/cbt.23622</ArticleId><ArticleId IdType="pmc">PMC3667868</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Rev Genet. 2004 Jul;5(7):522-31</Citation><ArticleIdList><ArticleId IdType="pubmed">15211354</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Oncol. 1999 Oct;15(4):793-802</Citation><ArticleIdList><ArticleId IdType="pubmed">10493964</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Signal. 2010 Aug 18;5:14</Citation><ArticleIdList><ArticleId IdType="pubmed">20718984</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2005 Jul 1;65(13):5506-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15994920</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2007 Feb 1;67(3):1030-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17283135</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2005 Dec 1;65(23):10946-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16322242</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2010 Apr 16;394(4):1098-104</Citation><ArticleIdList><ArticleId IdType="pubmed">20350531</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cancer Ther. 2009 Feb;8(2):310-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19174553</ArticleId></ArticleIdList></Reference><Reference><Citation>Breast Cancer Res Treat. 2009 Jan;113(1):101-11</Citation><ArticleIdList><ArticleId IdType="pubmed">18256928</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO Mol Med. 2010 Sep;2(9):371-84</Citation><ArticleIdList><ArticleId IdType="pubmed">20721990</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2008 Jun 5;27(25):3576-86</Citation><ArticleIdList><ArticleId IdType="pubmed">18212742</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2009 Feb 15;15(4):1177-83</Citation><ArticleIdList><ArticleId IdType="pubmed">19228723</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Mol Med. 2011 Jan;15(1):166-78</Citation><ArticleIdList><ArticleId IdType="pubmed">19874425</ArticleId></ArticleIdList></Reference><Reference><Citation>Planta Med. 2008 Nov;74(14):1693-700</Citation><ArticleIdList><ArticleId IdType="pubmed">18951337</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2010 Jun 1;70(11):4687-97</Citation><ArticleIdList><ArticleId IdType="pubmed">20484035</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2009 Sep;137(3):1102-13</Citation><ArticleIdList><ArticleId IdType="pubmed">19501590</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2010 Jan 15;70(2):709-18</Citation><ArticleIdList><ArticleId IdType="pubmed">20068161</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Stem Cell. 2009 Aug 7;5(2):168-77</Citation><ArticleIdList><ArticleId IdType="pubmed">19664991</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2010 Jan 1;16(1):154-63</Citation><ArticleIdList><ArticleId IdType="pubmed">20048334</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Cancer. 2005 Apr;5(4):275-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15803154</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Physiol Biochem Pharmacol. 2003;149:39-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12811586</ArticleId></ArticleIdList></Reference><Reference><Citation>Neoplasia. 2011 Jun;13(6):492-503</Citation><ArticleIdList><ArticleId IdType="pubmed">21677873</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2009 Apr;117(4):445-56</Citation><ArticleIdList><ArticleId IdType="pubmed">19214542</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2010 May 1;16(9):2580-90</Citation><ArticleIdList><ArticleId IdType="pubmed">20388854</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Drug Targets Inflamm Allergy. 2005 Feb;4(1):3-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15720228</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Stem Cell. 2007 Oct 11;1(4):389-402</Citation><ArticleIdList><ArticleId IdType="pubmed">18371377</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1994 Feb 17;367(6464):645-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7509044</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Cycle. 2008 May 15;7(10):1360-70</Citation><ArticleIdList><ArticleId IdType="pubmed">18418062</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Biol. 2007 Aug 7;17(15):1298-307</Citation><ArticleIdList><ArticleId IdType="pubmed">17656095</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2008 Mar;15(3):504-14</Citation><ArticleIdList><ArticleId IdType="pubmed">18049477</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomaterials. 2012 Feb;33(5):1462-76</Citation><ArticleIdList><ArticleId IdType="pubmed">22098779</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2004 Jun 15;64(12):4346-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15205350</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2007 Jan 4;445(7123):106-10</Citation><ArticleIdList><ArticleId IdType="pubmed">17122772</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Hematol. 2009 Mar;16(2):84-91</Citation><ArticleIdList><ArticleId IdType="pubmed">19468269</ArticleId></ArticleIdList></Reference><Reference><Citation>Anticancer Res. 2010 Dec;30(12):4915-20</Citation><ArticleIdList><ArticleId IdType="pubmed">21187470</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Lett. 2009 Oct 18;284(1):71-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19457609</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Biotechnol. 2007 Oct;18(5):460-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18023337</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cancer Ther. 2008 Sep;7(9):2725-35</Citation><ArticleIdList><ArticleId IdType="pubmed">18790753</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83</Citation><ArticleIdList><ArticleId IdType="pubmed">14645703</ArticleId></ArticleIdList></Reference><Reference><Citation>Autophagy. 2010 Jul;6(5):670-1</Citation><ArticleIdList><ArticleId IdType="pubmed">20559023</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2010;5(9). pii: e12487. doi: 10.1371/journal.pone.0012487</Citation><ArticleIdList><ArticleId IdType="pubmed">20824134</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunopharmacol Immunotoxicol. 2011 Jun;33(2):241-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20929432</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cancer. 2007 Mar;43(5):935-46</Citation><ArticleIdList><ArticleId IdType="pubmed">17320377</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Mol Med. 2009 Sep;13(9B):4023-33</Citation><ArticleIdList><ArticleId IdType="pubmed">20196789</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Oncol. 2010 Sep;37(3):551-61</Citation><ArticleIdList><ArticleId IdType="pubmed">20664924</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Markers. 2009;26(1):27-34</Citation><ArticleIdList><ArticleId IdType="pubmed">19242066</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene Ther. 2008 May;15(10):730-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18401438</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Oncol. 2011 Dec;28 Suppl 1:S99-107</Citation><ArticleIdList><ArticleId IdType="pubmed">21069479</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2007 Jun 28;447(7148):1130-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17554337</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanomedicine. 2011 Feb;7(1):69-79</Citation><ArticleIdList><ArticleId IdType="pubmed">20620237</ArticleId></ArticleIdList></Reference><Reference><Citation>Stem Cells. 2007 Oct;25(10):2524-33</Citation><ArticleIdList><ArticleId IdType="pubmed">17628016</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2008 Jul 15;68(14):5533-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18632604</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Signal. 2008 Dec 01;3:18</Citation><ArticleIdList><ArticleId IdType="pubmed">19046439</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Lett. 2013 Jan 28;328(2):261-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23041621</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2009 Oct 1;69(19):7507-11</Citation><ArticleIdList><ArticleId IdType="pubmed">19752085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2003 Sep 15;63(18):5821-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14522905</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Cancer. 2008;8:266</Citation><ArticleIdList><ArticleId IdType="pubmed">18803879</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2008 Jul 15;68(14):5658-68</Citation><ArticleIdList><ArticleId IdType="pubmed">18632618</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2008 Sep 5;373(4):567-71</Citation><ArticleIdList><ArticleId IdType="pubmed">18590703</ArticleId></ArticleIdList></Reference><Reference><Citation>J Control Release. 2008 Jul 2;129(1):18-25</Citation><ArticleIdList><ArticleId IdType="pubmed">18466993</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2004 Oct 1;64(19):7011-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15466194</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Discov Today. 2004 Sep 1;9(17):759-68</Citation><ArticleIdList><ArticleId IdType="pubmed">15450242</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Mol Med. 2008 Dec;12(6B):2628-43</Citation><ArticleIdList><ArticleId IdType="pubmed">18373740</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Biol Ther. 2007 Sep;6(9):1490-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17881904</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2010 May 1;16(9):2505-11</Citation><ArticleIdList><ArticleId IdType="pubmed">20388847</ArticleId></ArticleIdList></Reference><Reference><Citation>Gynecol Oncol. 2011 May 1;121(2):390-4</Citation><ArticleIdList><ArticleId IdType="pubmed">21272926</ArticleId></ArticleIdList></Reference><Reference><Citation>Stem Cells. 2009 Dec;27(12):2875-83</Citation><ArticleIdList><ArticleId IdType="pubmed">19816957</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biochem. 2012 Nov;370(1-2):89-102</Citation><ArticleIdList><ArticleId IdType="pubmed">22829019</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Lett. 2010 Jul 1;293(1):65-72</Citation><ArticleIdList><ArticleId IdType="pubmed">20089354</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2012 Jul;19(7):1208-19</Citation><ArticleIdList><ArticleId IdType="pubmed">22261616</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Cancer Inst. 2009 Apr 15;101(8):546-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19351923</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 2011 May 1;128(9):2182-91</Citation><ArticleIdList><ArticleId IdType="pubmed">20617516</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2001 Nov 1;414(6859):105-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11689955</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009;4(8):e6816</Citation><ArticleIdList><ArticleId IdType="pubmed">19714243</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18765800</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2007 Jan 4;445(7123):111-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17122771</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2005 Jul 15;65(14):6029-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16024602</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 1997 Jul;3(7):730-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9212098</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2005 Aug 15;65(16):7065-70</Citation><ArticleIdList><ArticleId IdType="pubmed">16103053</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 2011 Apr 1;117(7):1516-28</Citation><ArticleIdList><ArticleId IdType="pubmed">21425153</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2005 Jun 4;330(7503):1304-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15849206</ArticleId></ArticleIdList></Reference><Reference><Citation>Recent Results Cancer Res. 2010;184:221-34</Citation><ArticleIdList><ArticleId IdType="pubmed">20072842</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12629218</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Cell. 2008 Feb;13(2):153-66</Citation><ArticleIdList><ArticleId IdType="pubmed">18242515</ArticleId></ArticleIdList></Reference><Reference><Citation>RNA. 2008 Nov;14(11):2348-60</Citation><ArticleIdList><ArticleId IdType="pubmed">18812439</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 1996 Jul;14(7):836-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9631006</ArticleId></ArticleIdList></Reference><Reference><Citation>Breast Cancer Res Treat. 2010 Aug;123(1):271-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20135346</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Cancer. 2010 Nov 23;103(11):1692-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21063402</ArticleId></ArticleIdList></Reference><Reference><Citation>Stem Cells. 2008 Dec;26(12):3008-17</Citation><ArticleIdList><ArticleId IdType="pubmed">18802032</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2009 Aug 21;138(4):645-59</Citation><ArticleIdList><ArticleId IdType="pubmed">19682730</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2008 May 1;14(9):2813-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18451249</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cancer. 2012 Nov;48(17):3310-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22640830</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuro Oncol. 2011 Jan;13(1):61-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21062796</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncologist. 2001;6(1):34-55</Citation><ArticleIdList><ArticleId IdType="pubmed">11161227</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2010 Nov 15;70(22):9494-504</Citation><ArticleIdList><ArticleId IdType="pubmed">21062983</ArticleId></ArticleIdList></Reference><Reference><Citation>Gynecol Oncol. 2010 Jan;116(1):92-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19822355</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001060 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001060 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:23358473
|texte= Therapeutic strategies targeting cancer stem cells.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:23358473" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |